Effects of norplant on endometrial tissue factor expression and blood vessel structure.
Abnormal uterine bleeding after Norplant administration is primarily responsible for the high discontinuation rate of this safe and effective long-acting implantable progestin-only contraceptive agent. Although tissue factor (TF) is the primary initiator of hemostasis, previous studies indicated that Norplant-associated bleeding persists despite relatively high TF levels in the stromal compartment. Recently, we determined that progestin-enhanced TF expression during decidualization of human endometrial stromal cells involves both the epidermal growth factor receptor and progesterone receptor (PR]. The current study evaluated TF levels in endometrial bleeding (BL) and nonbleeding (NBL) sites obtained by camera-guided hysteroscopy during Norplant contraception. After 1 yr of therapy, immunohistochemical TF levels were unexpectedly higher at BL than at NBL sites. Use of immunohistochemistry and Western blotting indicated that both sites displayed elevated epidermal growth factor receptor levels and that the BL sites exhibited high levels of the PR, as well as the PR(A) and the PR(B) isoforms. Microscopic examination of 1-yr biopsies revealed that significantly larger numbers of enlarged, distended vessels were present in BL, compared with NBL sites. Elevated TF levels and abnormally enlarged blood vessels in the BL sites are consistent with the recently discovered angiogenic role of TF. By promoting aberrant angiogenesis, chronic endometrial overexpression of TF could produce fragile vessels, which are at increased risk to bleed. Analysis of endometrial BL and NBL sites, during Norplant contraception, offers the potential of elucidating local mechanisms that control enhanced TF expression, leading to abnormal angiogenesis at specific endometrial sites.
Runic
R
R
Department of Obstetrics and Gynecology, New York University School of Medicine, New York 10016, USA.
Schatz
F
F
Wan
L
L
Demopoulos
R
R
Krikun
G
G
Lockwood
C J
CJ
D000328:Adult; D001808:Blood Vessels / Q000033:anatomy & histology* / Q000187:drug effects; D015153:Blotting, Western; D003271:Contraceptive Agents, Female / Q000494:pharmacology*; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D016912:Levonorgestrel / Q000494:pharmacology*; D011980:Receptors, Progesterone / Q000187:drug effects / Q000378:metabolism; D013925:Thromboplastin / Q000096:biosynthesis*
D003271:Contraceptive Agents, Female; D011980:Receptors, Progesterone; D016912:Levonorgestrel; D013925:Thromboplastin